Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care...
Uložené v:
| Vydané v: | Circulation (New York, N.Y.) Ročník 133; číslo 15; s. 1472 - 83; discussion 1483 |
|---|---|
| Hlavní autori: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
12.04.2016
|
| Predmet: | |
| ISSN: | 1524-4539 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS.
Patients with symptomatic femoropopliteal artery disease were randomly assigned to DES (n=236) or PTA (n=238). Approximately 91% had claudication; 9% had critical limb ischemia. Patients experiencing acute PTA failure underwent secondary randomization to provisional BMS (n=59) or DES (n=61). The 1-year primary end points of event-free survival and patency showed superiority of primary DES in comparison with PTA; these results were sustained through 5 years. Clinical benefit (freedom from persistent or worsening symptoms of ischemia; 79.8% versus 59.3%, P<0.01), patency (66.4% versus 43.4%, P<0.01), and freedom from reintervention (target lesion revascularization, 83.1% versus 67.6%, P<0.01) for the overall DES group were superior to standard care in nonrandomized comparisons. Similarly, clinical benefit (81.8% versus 63.8%, P=0.02), patency (72.4% versus 53.0%, P=0.03), and freedom from target lesion revascularization (84.9% versus 71.6%, P=0.06) with provisional DES were improved over provisional BMS. These results represent >40% relative risk reduction for restenosis and target lesion revascularization through 5 years for the overall DES in comparison with standard care and for provisional DES in comparison with provisional BMS.
The 5-year results from this large study provide long-term information previously unavailable regarding endovascular treatment of femoropopliteal artery disease. The Zilver PTX DES provided sustained safety and clinical durability in comparison with standard endovascular treatments.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00120406. |
|---|---|
| AbstractList | This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS.
Patients with symptomatic femoropopliteal artery disease were randomly assigned to DES (n=236) or PTA (n=238). Approximately 91% had claudication; 9% had critical limb ischemia. Patients experiencing acute PTA failure underwent secondary randomization to provisional BMS (n=59) or DES (n=61). The 1-year primary end points of event-free survival and patency showed superiority of primary DES in comparison with PTA; these results were sustained through 5 years. Clinical benefit (freedom from persistent or worsening symptoms of ischemia; 79.8% versus 59.3%, P<0.01), patency (66.4% versus 43.4%, P<0.01), and freedom from reintervention (target lesion revascularization, 83.1% versus 67.6%, P<0.01) for the overall DES group were superior to standard care in nonrandomized comparisons. Similarly, clinical benefit (81.8% versus 63.8%, P=0.02), patency (72.4% versus 53.0%, P=0.03), and freedom from target lesion revascularization (84.9% versus 71.6%, P=0.06) with provisional DES were improved over provisional BMS. These results represent >40% relative risk reduction for restenosis and target lesion revascularization through 5 years for the overall DES in comparison with standard care and for provisional DES in comparison with provisional BMS.
The 5-year results from this large study provide long-term information previously unavailable regarding endovascular treatment of femoropopliteal artery disease. The Zilver PTX DES provided sustained safety and clinical durability in comparison with standard endovascular treatments.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00120406. BACKGROUNDThis randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS.METHODS AND RESULTSPatients with symptomatic femoropopliteal artery disease were randomly assigned to DES (n=236) or PTA (n=238). Approximately 91% had claudication; 9% had critical limb ischemia. Patients experiencing acute PTA failure underwent secondary randomization to provisional BMS (n=59) or DES (n=61). The 1-year primary end points of event-free survival and patency showed superiority of primary DES in comparison with PTA; these results were sustained through 5 years. Clinical benefit (freedom from persistent or worsening symptoms of ischemia; 79.8% versus 59.3%, P<0.01), patency (66.4% versus 43.4%, P<0.01), and freedom from reintervention (target lesion revascularization, 83.1% versus 67.6%, P<0.01) for the overall DES group were superior to standard care in nonrandomized comparisons. Similarly, clinical benefit (81.8% versus 63.8%, P=0.02), patency (72.4% versus 53.0%, P=0.03), and freedom from target lesion revascularization (84.9% versus 71.6%, P=0.06) with provisional DES were improved over provisional BMS. These results represent >40% relative risk reduction for restenosis and target lesion revascularization through 5 years for the overall DES in comparison with standard care and for provisional DES in comparison with provisional BMS.CONCLUSIONSThe 5-year results from this large study provide long-term information previously unavailable regarding endovascular treatment of femoropopliteal artery disease. The Zilver PTX DES provided sustained safety and clinical durability in comparison with standard endovascular treatments.CLINICAL TRIAL REGISTRATIONURL: http://www.clinicaltrials.gov. Unique identifier: NCT00120406. |
| Author | Dake, Michael D Ansel, Gary M O'Leary, Erin E Saxon, Richard R Smouse, H Bob Ohki, Takao Machan, Lindsay S Snyder, Scott A Jaff, Michael R Zeller, Thomas Ragheb, Anthony O |
| Author_xml | – sequence: 1 givenname: Michael D surname: Dake fullname: Dake, Michael D email: mddake@stanford.edu organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.). mddake@stanford.edu – sequence: 2 givenname: Gary M surname: Ansel fullname: Ansel, Gary M organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 3 givenname: Michael R surname: Jaff fullname: Jaff, Michael R organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 4 givenname: Takao surname: Ohki fullname: Ohki, Takao organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 5 givenname: Richard R surname: Saxon fullname: Saxon, Richard R organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 6 givenname: H Bob surname: Smouse fullname: Smouse, H Bob organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 7 givenname: Lindsay S surname: Machan fullname: Machan, Lindsay S organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 8 givenname: Scott A surname: Snyder fullname: Snyder, Scott A organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 9 givenname: Erin E surname: O'Leary fullname: O'Leary, Erin E organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 10 givenname: Anthony O surname: Ragheb fullname: Ragheb, Anthony O organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) – sequence: 11 givenname: Thomas surname: Zeller fullname: Zeller, Thomas organization: From Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA (M.D.D.); Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus (G.M.A.); The Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); Department of Surgery, Jikei University Hospital, Tokyo, Japan (T.O.); Department of Diagnostic Imaging and Interventional Radiology, Tri-City Medical Center, Oceanside, CA (R.R.S.); Department of Radiology, OSF St. Francis Medical Center, Peoria, IL (H.B.S.); Department of Radiology, The University of British Columbia, Vancouver, Canada (L.S.M.); Cook Research Incorporated, West Lafayette, IN (S.A.S., E.E.O'L., A.O.R.); and Department of Angiology, Herz Zentrum, Bad Krozingen, Germany (T.Z.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26969758$$D View this record in MEDLINE/PubMed |
| BookMark | eNo10M1O4zAUhmELMeL_FpDZsQnYcewk7KLQTitVU9QpmoFN5TjHYOQ4HdtBwEVwzUTArI706dG7OIdo1_UOEDqj5IJSQS_r-aq-XVTr-fJXNavGjV8QKkpCdtAB5WmWZJyV--gwhCdCiGA530P7qShFmfPiAL1fD142FnBtjTNKWjzRGlQ0z-AgBPzHxEd8I5U1Ub6ATSZ2iMY94N8RXAzYOBwfAU-h632_7bcjg7FR-Qj-9Qrz5A6kxysIgx11rz_1vbHP4PHN-i9eSdf2nXmDFq-9kfYY_dDSBjj5vkfodjpZ17Nksfw5r6tForKckgQaQlPNmM6VpLIBnjEmoVBMZLQhwLXUqRCMtKLUWlEQKmNtq2jRiqLMCUuP0PlXd-v7fwOEuOlMUGCtdNAPYUPzghSUj42Rnn7Toemg3Wy96aR_3fz_YfoBOgF4BQ |
| CitedBy_id | crossref_primary_10_23736_S0021_9509_21_11679_9 crossref_primary_10_23736_S0021_9509_19_11035_X crossref_primary_10_1016_j_jcin_2018_03_010 crossref_primary_10_1016_j_jcin_2022_01_022 crossref_primary_10_1177_1358863X221148521 crossref_primary_10_1007_s11239_023_02932_5 crossref_primary_10_1016_j_ejvs_2019_01_006 crossref_primary_10_1055_s_0043_57261 crossref_primary_10_1177_1358863X241290233 crossref_primary_10_1016_j_pmatsci_2025_101541 crossref_primary_10_1161_CIRCINTERVENTIONS_118_007702 crossref_primary_10_1016_j_jvir_2018_02_006 crossref_primary_10_1016_j_jvs_2019_09_053 crossref_primary_10_1177_15266028241292464 crossref_primary_10_1177_1526602820952413 crossref_primary_10_1177_17085381221126217 crossref_primary_10_1177_1526602819896293 crossref_primary_10_23736_S0392_9590_22_04959_8 crossref_primary_10_3389_fpubh_2025_1488091 crossref_primary_10_1016_j_jvs_2017_10_076 crossref_primary_10_1177_1526602817725062 crossref_primary_10_1111_acel_13832 crossref_primary_10_1177_1526602820966708 crossref_primary_10_1038_s41598_021_97675_9 crossref_primary_10_1161_JAHA_122_028622 crossref_primary_10_1002_ccd_26863 crossref_primary_10_1016_j_jvs_2022_06_093 crossref_primary_10_1007_s00270_018_2095_9 crossref_primary_10_1016_j_jvir_2017_12_006 crossref_primary_10_1002_ccd_30441 crossref_primary_10_1007_s00108_018_0549_4 crossref_primary_10_1016_j_jvs_2019_05_034 crossref_primary_10_1016_j_jvs_2019_04_468 crossref_primary_10_1007_s11936_019_0769_5 crossref_primary_10_1016_j_jvir_2021_02_014 crossref_primary_10_1007_s00380_020_01695_w crossref_primary_10_1016_j_avsg_2019_11_044 crossref_primary_10_15829_1728_8800_2019_2274 crossref_primary_10_1016_j_jvs_2020_05_061 crossref_primary_10_3390_jcm12196343 crossref_primary_10_1016_j_avsg_2016_08_050 crossref_primary_10_1016_j_ejvs_2020_04_008 crossref_primary_10_23736_S0021_9509_19_10984_6 crossref_primary_10_1016_j_ahj_2019_12_012 crossref_primary_10_1177_1526602819884062 crossref_primary_10_3390_jcdd9070207 crossref_primary_10_1001_jamainternmed_2021_2738 crossref_primary_10_23736_S0021_9509_22_12341_4 crossref_primary_10_1016_j_jcin_2022_01_019 crossref_primary_10_1177_1526602818820787 crossref_primary_10_1016_j_jvs_2024_12_135 crossref_primary_10_1161_CIRCULATIONAHA_117_024469 crossref_primary_10_1016_j_pcad_2018_03_003 crossref_primary_10_1007_s11814_022_1286_x crossref_primary_10_1007_s12928_020_00744_5 crossref_primary_10_1016_j_jvir_2017_08_014 crossref_primary_10_1016_j_jacc_2024_02_023 crossref_primary_10_1016_j_jvir_2016_06_008 crossref_primary_10_1002_ccd_31447 crossref_primary_10_1016_j_avsg_2024_02_017 crossref_primary_10_1016_j_avsg_2018_05_051 crossref_primary_10_1038_s41598_024_71745_0 crossref_primary_10_1007_s00772_017_0296_1 crossref_primary_10_1017_S0266462321000532 crossref_primary_10_1002_ccd_29125 crossref_primary_10_1016_j_jvs_2019_06_198 crossref_primary_10_1055_s_0042_1758078 crossref_primary_10_1016_j_atherosclerosis_2021_09_012 crossref_primary_10_1016_j_avsg_2023_03_028 crossref_primary_10_1093_eurheartj_ehx095 crossref_primary_10_1097_MJT_0000000000000916 crossref_primary_10_1177_1526602818824682 crossref_primary_10_1007_s00270_016_1500_5 crossref_primary_10_1016_j_avsg_2018_04_014 crossref_primary_10_1016_j_jacc_2018_12_009 crossref_primary_10_1016_j_avsg_2024_05_035 crossref_primary_10_1177_1526602819849955 crossref_primary_10_1016_j_jacc_2024_02_013 crossref_primary_10_1161_CIRCINTERVENTIONS_123_013084 crossref_primary_10_1016_j_jvir_2024_08_024 crossref_primary_10_1016_j_jcin_2018_03_046 crossref_primary_10_1016_j_cpcardiol_2021_101082 crossref_primary_10_1016_j_cpcardiol_2024_102430 crossref_primary_10_1002_hsr2_1481 crossref_primary_10_1161_CIR_0000000000001192 crossref_primary_10_1007_s00108_019_00695_x crossref_primary_10_3390_jcdd10030126 crossref_primary_10_1016_j_ejvs_2022_08_004 crossref_primary_10_1177_1526602817749242 crossref_primary_10_3390_medicina58091225 crossref_primary_10_1007_s00380_020_01740_8 crossref_primary_10_23736_S0021_9509_21_11633_7 crossref_primary_10_2174_1389201021666201126143217 crossref_primary_10_1002_ccd_27523 crossref_primary_10_1016_j_jcin_2018_08_034 crossref_primary_10_1007_s00270_022_03214_y crossref_primary_10_1016_j_avsg_2020_05_040 crossref_primary_10_1016_j_jcin_2017_12_015 crossref_primary_10_1177_15266028251344877 crossref_primary_10_1016_j_avsg_2023_04_001 crossref_primary_10_1016_j_jcin_2016_10_001 crossref_primary_10_1016_j_jscai_2023_100981 crossref_primary_10_1080_14779072_2017_1408409 crossref_primary_10_1007_s00270_019_02329_z crossref_primary_10_1016_j_ejrad_2017_03_015 crossref_primary_10_1177_1358863X20987894 crossref_primary_10_1161_JAHA_121_020834 crossref_primary_10_1177_1526602820948472 crossref_primary_10_1186_s42155_019_0069_x crossref_primary_10_1515_bmt_2022_0412 crossref_primary_10_1016_j_jvs_2017_05_110 crossref_primary_10_1177_1526602820931477 crossref_primary_10_1177_15266028241271725 crossref_primary_10_1177_15385744251358129 crossref_primary_10_1007_s00270_019_02355_x crossref_primary_10_1016_j_jvs_2025_02_050 crossref_primary_10_1177_1526602818779826 crossref_primary_10_1002_ccd_29267 crossref_primary_10_1053_j_semvascsurg_2021_10_009 crossref_primary_10_1016_j_jacc_2019_01_078 crossref_primary_10_1007_s00772_019_0516_y crossref_primary_10_17925_HI_2021_15_2_73 crossref_primary_10_1016_j_amjcard_2023_07_172 crossref_primary_10_1016_j_jcin_2021_08_058 crossref_primary_10_1002_ccd_27198 crossref_primary_10_1016_j_avsg_2020_08_147 crossref_primary_10_1016_j_jcin_2019_12_028 crossref_primary_10_1161_CIRCULATIONAHA_119_044697 crossref_primary_10_1177_1526602818806858 crossref_primary_10_1007_s00270_017_1771_5 crossref_primary_10_1016_j_carrev_2023_12_017 crossref_primary_10_1177_15266028211067726 crossref_primary_10_1016_j_avsg_2023_11_024 crossref_primary_10_1161_JAHA_119_012524 crossref_primary_10_1161_JAHA_119_012523 crossref_primary_10_1016_j_pcad_2021_11_008 crossref_primary_10_1016_j_avsg_2023_01_043 crossref_primary_10_1177_1526602819870309 crossref_primary_10_1177_1526602820907917 crossref_primary_10_1002_ccd_27635 crossref_primary_10_1016_j_jvir_2023_12_574 crossref_primary_10_1016_j_jvir_2023_02_006 crossref_primary_10_1177_17085381241297765 crossref_primary_10_1016_j_cjca_2022_02_029 crossref_primary_10_1093_eurheartj_ehac722 crossref_primary_10_1002_ccd_31245 crossref_primary_10_1016_j_jscai_2022_100439 crossref_primary_10_1016_j_jacc_2019_04_018 crossref_primary_10_1177_1526602819833065 crossref_primary_10_1016_j_carrev_2020_06_014 crossref_primary_10_1161_JAHA_118_011245 crossref_primary_10_1016_j_ejvs_2019_12_034 crossref_primary_10_1016_j_jcin_2019_12_030 crossref_primary_10_1016_j_jvs_2020_02_026 crossref_primary_10_1016_j_jacc_2021_08_046 crossref_primary_10_1016_j_jcin_2019_09_013 crossref_primary_10_1177_1526602818769390 crossref_primary_10_1016_j_bioactmat_2024_03_018 crossref_primary_10_1016_j_ejvsvf_2024_08_001 crossref_primary_10_1016_j_xplc_2025_101460 crossref_primary_10_1177_1526602820901723 crossref_primary_10_1016_j_mayocp_2020_01_035 crossref_primary_10_1161_CIRCINTERVENTIONS_116_004450 crossref_primary_10_1080_17425247_2016_1230098 crossref_primary_10_1016_j_jvs_2017_06_112 crossref_primary_10_1371_journal_pone_0248416 crossref_primary_10_1016_j_jacc_2019_05_050 crossref_primary_10_1016_j_ejvs_2019_09_002 crossref_primary_10_1007_s11428_023_01141_1 crossref_primary_10_4081_jphr_2021_2360 crossref_primary_10_1371_journal_pone_0291466 crossref_primary_10_1016_j_avsg_2020_08_003 crossref_primary_10_1016_j_avsg_2020_08_124 crossref_primary_10_1016_j_tvir_2022_100840 crossref_primary_10_1007_s00270_021_02848_8 crossref_primary_10_1016_j_tvir_2022_100842 crossref_primary_10_1039_C9RA06179G crossref_primary_10_17816_MAJ296568 crossref_primary_10_1007_s11428_023_01043_2 crossref_primary_10_1016_j_jcin_2019_09_006 crossref_primary_10_1177_1526602819857241 crossref_primary_10_1177_1358863X231174052 crossref_primary_10_1016_j_ejvs_2023_07_038 crossref_primary_10_1016_j_jvs_2023_01_207 crossref_primary_10_1161_CIRCINTERVENTIONS_118_006564 crossref_primary_10_1016_j_ejvs_2023_08_067 crossref_primary_10_3390_ijms25168749 crossref_primary_10_1016_j_ahj_2018_12_012 crossref_primary_10_1177_1526602820904783 crossref_primary_10_1007_s15027_019_1675_1 crossref_primary_10_1016_j_jvs_2019_05_002 crossref_primary_10_1186_s42155_024_00465_3 crossref_primary_10_1016_j_jcin_2016_04_002 crossref_primary_10_1016_j_suc_2023_05_002 crossref_primary_10_1016_S0140_6736_18_32339_0 crossref_primary_10_1007_s00270_023_03549_0 crossref_primary_10_1177_17085381251342326 crossref_primary_10_1016_j_avsg_2017_04_021 crossref_primary_10_57264_cer_2024_0025 crossref_primary_10_1016_j_amjcard_2024_07_016 crossref_primary_10_1161_CIRCULATIONAHA_119_041099 crossref_primary_10_1080_17425247_2025_2476043 crossref_primary_10_1038_s41569_018_0005_0 crossref_primary_10_23736_S0392_9590_22_04763_0 crossref_primary_10_1016_j_avsg_2022_04_047 crossref_primary_10_1007_s00772_020_00726_0 crossref_primary_10_1161_CIRCULATIONAHA_122_062255 crossref_primary_10_1016_j_jcin_2021_01_026 crossref_primary_10_1007_s00270_021_02901_6 crossref_primary_10_1177_1526602820960445 crossref_primary_10_1016_j_jvs_2021_05_058 crossref_primary_10_5604_01_3001_0015_9578 crossref_primary_10_1016_j_ijcard_2018_02_040 crossref_primary_10_1002_ccd_27569 crossref_primary_10_1016_j_jvsvi_2024_100089 crossref_primary_10_1186_s42155_024_00435_9 crossref_primary_10_1002_ccd_28645 crossref_primary_10_1055_a_2540_3349 crossref_primary_10_1161_CIR_0000000000001005 crossref_primary_10_1016_j_ejvs_2020_03_010 crossref_primary_10_1016_j_jcin_2017_03_005 crossref_primary_10_23736_S0021_9509_24_13129_1 crossref_primary_10_1016_j_jcin_2018_01_233 crossref_primary_10_1007_s11936_019_0765_9 crossref_primary_10_1161_CIRCINTERVENTIONS_117_006285 crossref_primary_10_1161_CIR_0000000000001251 crossref_primary_10_1016_j_jcin_2024_11_038 crossref_primary_10_1007_s00270_020_02693_1 crossref_primary_10_1016_j_avsg_2023_11_061 crossref_primary_10_23736_S0021_9509_19_10965_2 crossref_primary_10_1016_j_ejvs_2018_08_001 crossref_primary_10_1016_j_jacc_2018_11_039 crossref_primary_10_3389_fcvm_2022_877578 crossref_primary_10_1007_s11428_022_00904_6 crossref_primary_10_1177_1526602816654889 crossref_primary_10_1016_j_jvs_2019_10_100 crossref_primary_10_1177_1526602819826591 crossref_primary_10_3348_jksr_2021_0036 crossref_primary_10_1177_1526602820921405 crossref_primary_10_1007_s00772_020_00633_4 crossref_primary_10_1016_j_avsg_2020_11_011 crossref_primary_10_1161_CIRCULATIONAHA_116_022039 crossref_primary_10_3390_medicina58091293 crossref_primary_10_1371_journal_pone_0270992 crossref_primary_10_1024_0301_1526_a001213 crossref_primary_10_1177_15266028231179861 crossref_primary_10_1161_CIRCINTERVENTIONS_120_009322 crossref_primary_10_1016_j_yasu_2018_03_012 crossref_primary_10_1016_j_jcin_2024_03_015 crossref_primary_10_1007_s12928_022_00873_z crossref_primary_10_1371_journal_pone_0275888 crossref_primary_10_4103_jicc_jicc_37_22 crossref_primary_10_1056_NEJMoa2005206 crossref_primary_10_1186_s13063_024_08219_1 crossref_primary_10_1016_j_jacc_2016_11_007 crossref_primary_10_1016_j_jvs_2021_05_035 crossref_primary_10_23736_S0021_9509_19_10953_6 crossref_primary_10_1016_j_jvs_2016_10_098 crossref_primary_10_1016_j_jacc_2019_01_013 crossref_primary_10_1016_j_ejvs_2017_07_018 crossref_primary_10_1016_j_ijcard_2024_131977 crossref_primary_10_1016_j_jacc_2018_03_483 crossref_primary_10_1016_j_jvs_2018_01_058 crossref_primary_10_1177_1358863X19853623 crossref_primary_10_1177_2047487319846999 crossref_primary_10_1016_j_jvs_2019_11_041 crossref_primary_10_1016_j_ejvs_2019_06_012 crossref_primary_10_1016_j_jcin_2019_07_045 crossref_primary_10_1016_j_avsg_2021_02_024 crossref_primary_10_1007_s00270_020_02464_y crossref_primary_10_1161_CIRCINTERVENTIONS_117_005891 crossref_primary_10_1007_s11886_017_0926_y crossref_primary_10_1177_1358863X241228261 crossref_primary_10_1016_j_ejvs_2019_06_017 crossref_primary_10_1007_s00270_023_03589_6 crossref_primary_10_3348_jksr_2021_0057 crossref_primary_10_1016_S0140_6736_23_02189_X crossref_primary_10_1038_s41569_021_00531_6 crossref_primary_10_1161_CIRCINTERVENTIONS_121_011506 crossref_primary_10_1007_s12928_019_00573_1 crossref_primary_10_1016_j_avsg_2021_08_016 crossref_primary_10_1016_j_crvasa_2017_10_001 crossref_primary_10_1002_ccd_27484 crossref_primary_10_1016_j_jvs_2017_09_017 crossref_primary_10_1007_s00772_020_00713_5 crossref_primary_10_1016_j_jscai_2025_103616 crossref_primary_10_1177_15266028231205421 crossref_primary_10_1016_j_carrev_2019_02_006 crossref_primary_10_1016_j_iccl_2019_12_001 crossref_primary_10_3390_jcm14051704 crossref_primary_10_1007_s11428_025_01323_z crossref_primary_10_1016_j_iccl_2016_12_004 crossref_primary_10_3390_jcm9072221 crossref_primary_10_1007_s00270_018_2110_1 crossref_primary_10_1016_j_iccl_2016_12_006 crossref_primary_10_1080_17425247_2020_1789586 crossref_primary_10_1161_CIR_0000000000000471 crossref_primary_10_1053_j_semvascsurg_2022_04_010 crossref_primary_10_1016_j_cpcardiol_2018_09_004 crossref_primary_10_1177_15266028231202709 crossref_primary_10_17925_HI_2019_13_1_15 crossref_primary_10_1136_bmjopen_2016_013460 crossref_primary_10_1016_j_jvs_2021_08_062 crossref_primary_10_1177_00033197241263381 crossref_primary_10_1161_CIRCULATIONAHA_116_022546 crossref_primary_10_1016_j_jcin_2019_08_025 crossref_primary_10_1016_j_jvssci_2024_100277 crossref_primary_10_1016_j_avsg_2025_04_110 crossref_primary_10_1016_j_jvs_2023_01_195 crossref_primary_10_1177_15385744241253170 crossref_primary_10_1016_j_jvir_2017_08_003 crossref_primary_10_1016_j_jvs_2020_07_093 crossref_primary_10_1016_S0140_6736_18_32262_1 crossref_primary_10_1016_S0140_6736_25_01585_5 crossref_primary_10_1016_j_avsg_2019_09_032 crossref_primary_10_1177_15266028211023505 crossref_primary_10_1007_s11886_019_1211_z crossref_primary_10_1177_1526602819862778 crossref_primary_10_1177_1526602818762805 crossref_primary_10_3389_fcvm_2022_1022071 crossref_primary_10_1097_SLA_0000000000005413 crossref_primary_10_1002_ccd_31053 crossref_primary_10_1177_1526602817698897 crossref_primary_10_2217_fca_2017_0105 crossref_primary_10_1007_s00270_023_03507_w crossref_primary_10_1177_08971900241250084 crossref_primary_10_1016_j_pmatsci_2022_100922 crossref_primary_10_1161_JAHA_122_025677 crossref_primary_10_1177_1526602820950261 crossref_primary_10_5812_iranjradiol_111918 crossref_primary_10_1177_1526602819881156 crossref_primary_10_2459_JCM_0000000000000593 crossref_primary_10_1016_j_drudis_2016_05_019 crossref_primary_10_1007_s11886_021_01477_4 crossref_primary_10_1056_NEJMcp1709326 crossref_primary_10_1007_s10554_019_01638_1 crossref_primary_10_1016_j_jvir_2019_08_014 crossref_primary_10_1002_ccd_27141 crossref_primary_10_1080_03007995_2017_1372114 crossref_primary_10_1161_CIRCRESAHA_121_318261 crossref_primary_10_1016_j_ejvs_2025_03_010 crossref_primary_10_1177_1526602819860124 crossref_primary_10_1002_clc_23098 crossref_primary_10_1177_15266028231158294 crossref_primary_10_1016_j_avsg_2019_05_013 crossref_primary_10_23736_S0021_9509_19_11109_3 crossref_primary_10_1016_j_jvs_2025_04_041 crossref_primary_10_1016_j_avsg_2017_12_003 crossref_primary_10_1177_15385744211051491 crossref_primary_10_1007_s00380_017_0982_7 crossref_primary_10_1016_j_ejvs_2018_12_020 crossref_primary_10_1016_j_jvs_2025_04_029 crossref_primary_10_1177_15266028231198033 crossref_primary_10_1177_15266028211049339 crossref_primary_10_1177_1708538120964371 crossref_primary_10_1016_j_ijcard_2024_132108 crossref_primary_10_1177_1358863X19880602 crossref_primary_10_1007_s40256_018_0265_4 crossref_primary_10_1093_eurheartj_ehw643 crossref_primary_10_1161_CIRCOUTCOMES_120_007040 crossref_primary_10_1177_1358863X18802969 crossref_primary_10_1177_1538574420920994 crossref_primary_10_1016_j_iccl_2016_12_011 crossref_primary_10_1016_j_jcin_2017_05_055 crossref_primary_10_1161_CIRCINTERVENTIONS_119_008528 crossref_primary_10_23736_S0392_9590_19_04049_5 crossref_primary_10_1016_j_jvs_2018_02_040 crossref_primary_10_1016_j_jacc_2019_02_020 crossref_primary_10_1016_j_pcad_2021_02_002 crossref_primary_10_1177_1526602817743747 crossref_primary_10_1177_1538574420920998 crossref_primary_10_17106_jbr_36_3 crossref_primary_10_1177_1526602817708778 crossref_primary_10_1007_s12928_021_00774_7 crossref_primary_10_1016_j_pcad_2021_02_004 crossref_primary_10_1016_j_jcin_2023_04_002 crossref_primary_10_1161_JAHA_120_020289 |
| ContentType | Journal Article |
| Copyright | 2016 The Authors. |
| Copyright_xml | – notice: 2016 The Authors. |
| CorporateAuthor | Zilver PTX Investigators |
| CorporateAuthor_xml | – name: Zilver PTX Investigators |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1161/CIRCULATIONAHA.115.016900 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1524-4539 |
| EndPage | 83; discussion 1483 |
| ExternalDocumentID | 26969758 |
| Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACIJW ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY AE3 AE6 AEBDS AEETU AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIK DIWNM DU5 E3Z EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ZZMQN ~H1 7X8 AAFWJ ABPXF ABUFD ACBKD ADKSD ADSXY |
| ID | FETCH-LOGICAL-c4710-eb012f33f7ca1abe5433ae8c3641b0e5faf26630d69ffc1e6c43ddc18d6897032 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 438 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00003017-201604120-00007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Sun Nov 09 05:17:05 EST 2025 Thu Apr 03 07:10:18 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Keywords | paclitaxel drug-eluting stents peripheral artery disease stents angioplasty |
| Language | English |
| License | 2016 The Authors. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4710-eb012f33f7ca1abe5433ae8c3641b0e5faf26630d69ffc1e6c43ddc18d6897032 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4823823 |
| PMID | 26969758 |
| PQID | 1780815663 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1780815663 pubmed_primary_26969758 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-April-12 |
| PublicationDateYYYYMMDD | 2016-04-12 |
| PublicationDate_xml | – month: 04 year: 2016 text: 2016-April-12 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Circulation (New York, N.Y.) |
| PublicationTitleAlternate | Circulation |
| PublicationYear | 2016 |
| References | 26969757 - Circulation. 2016 Apr 12;133(15):1435-7 30779646 - Circulation. 2019 Feb 19;139(8):e42 |
| References_xml | – reference: 30779646 - Circulation. 2019 Feb 19;139(8):e42 – reference: 26969757 - Circulation. 2016 Apr 12;133(15):1435-7 |
| SSID | ssj0006375 |
| Score | 2.6513813 |
| Snippet | This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions.... BACKGROUNDThis randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1472 |
| SubjectTerms | Adult Aged Angioplasty Anticoagulants - therapeutic use Arterial Occlusive Diseases - drug therapy Arterial Occlusive Diseases - therapy Aspirin - therapeutic use Clopidogrel Combined Modality Therapy Disease Progression Disease-Free Survival Drug-Eluting Stents Equipment Failure Female Femoral Artery - drug effects Follow-Up Studies Humans Intermittent Claudication - therapy Ischemia - surgery Ischemia - therapy Male Middle Aged Paclitaxel - administration & dosage Paclitaxel - therapeutic use Popliteal Artery - drug effects Recurrence Stents Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Vascular Patency |
| Title | Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26969758 https://www.proquest.com/docview/1780815663 |
| Volume | 133 |
| WOSCitedRecordID | wos00003017-201604120-00007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1daxQxFL1UK6UvWlu1rVZuofgWupnMZGZ8kWXtUsEuy3aLqy9LJh86sJ1Z90Nsf4S_2ZvMlD4JQl_mYUggkJuTc5KbcwFOItLGKTcxMTdOAoXbmKmoUKxIpE5EoUlTmFBsIh0MsskkH7YHbss2rfIOEwNQm1r7M_JTnvoaEUQ-xIf5T-arRvnb1baExiPYFERlfFSnk3u3cCnSZAuOAzBIftr7NOpdfW5MZs-79M87dpI67PybXYZdpv_soePbgactv8RuExDPYcNWu7DXrUhbX9_gOwwZn-EofRe2LtqL9T3483G98I-osPUJnWFja9xiIX4pVz9wqLS39P5tZ-zMB2z1HS9XPhEDywqJSGLfp-3W83ruHzY3o7CLm_eYsK-0oHBkl-sZta5daP2t9FnZOBxPcKQqU1-Xt9bg2K-IF3DVPxv3zllbqoFp2t06zBa00TkhXKoVV4VNYiGUzbSQMS86NnHKERMQHSNz5zS3UsfCGM0zI7OcQCd6CY-rurL7gCazCTfOyjhXcayjnHSz9sijhJROqAM4vpuAKS0Ff7-hKluvl9P7KTiAV80sTueNZ8c0krnMSRsd_kfv17BNtEiy4Oj4BjYdAYE9gif616pcLt6GGKPvYHjxF9nK3hg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Durable+Clinical+Effectiveness+With+Paclitaxel-Eluting+Stents+in+the+Femoropopliteal+Artery%3A+5-Year+Results+of+the+Zilver+PTX+Randomized+Trial&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Dake%2C+Michael+D&rft.au=Ansel%2C+Gary+M&rft.au=Jaff%2C+Michael+R&rft.au=Ohki%2C+Takao&rft.date=2016-04-12&rft.eissn=1524-4539&rft.volume=133&rft.issue=15&rft.spage=1472&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.115.016900&rft_id=info%3Apmid%2F26969758&rft_id=info%3Apmid%2F26969758&rft.externalDocID=26969758 |